AveXis Announces the Completion of Enrollment for Phase 1 Gene Therapy Trial

AveXis has announced that they have completed enrollment in a Phase 1 study testing systemic delivery of gene therapy for SMA.

The trial has enrolled a total of 15 patients who met enrollment criteria of diagnosis of SMA Type 1 before six months of age, with two copies of the SMN2 backup gene, as determined by genetic testing. The trial includes two dosing cohorts:

  • Cohort 1 includes three patients dosed at (6.7 X1013 vg/kg), aged six to seven months at time of dosing;
  • Cohort 2 includes 12 patients dosed at (2.0 X1014 vg/kg), aged one to eight months at time of dosing.

“We are pleased to have reached this important initial clinical milestone in our effort to bring AVXS -101 to patients who suffer from SMA Type 1, a devastating disease for which there are currently no FDA-approved therapies,” said Sean Nolan, President and Chief Executive Officer of AveXis. “The data from this initial trial will inform future clinical studies in Type 1 and potentially other types of SMA. We look forward to reviewing the data from this study over the coming year as we continue the development of AVXS-101.”

For more information, visit the AveXis website or Clinicaltrials.gov.

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top